OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis. 2014

Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

There is an urgent requirement for a novel vaccine that can stimulate immune responses without unwanted toxicity, including IgE elevation. We examined whether antigen ovalbumin (OVA) conjugated to the surface of nanoparticles (NPs) (OVA-NPs) with average diameter of 110nm would serve as an immune adjuvant. When BALB/c mice were immunized with OVA-NPs, they developed sufficient levels of OVA-specific IgG1 antibody responses with low levels of IgE synthesis, representing helper T (Th)2-mediated humoral immunity. OVA-specific IgG2a and IgG2b responses (i.e., Th1-mediated immunity) were also induced by secondary immunization with OVA-NPs. As expected, immunization with OVA in alum (OVA-alum) stimulated humoral immune responses, including IgG1 and IgE antibodies, with only low levels of IgG2a/IgG2b antibodies. CD4-positive T cells from mice primed with OVA-NPs produced substantial levels of IL-21 and IL-4, comparable to those from OVA-alum group. The irradiated mice receiving OVA-NPs-primed B cells together with OVA-alum-primed T cells exhibited enhanced anti-OVA IgG2b responses relative to OVA-alum-primed B cells and T cells following stimulation with OVA-NPs. Moreover, when OVA-NPs-primed, but not OVA-alum-primed, B cells were cultured in the presence of anti-CD40 monoclonal antibody, IL-4, and IL-21, or LPS plus TGF-β in vitro, OVA-specific IgG1 or IgG2b antibody responses were elicited, suggesting that immunization with OVA-NPs modulates B cells to generate IgG1 and IgG2b responses. Thus, OVA-NPs might exert their adjuvant action on B cells, and they represent a promising potential vaccine for generating both IgG1 and IgG2a/IgG2b antibody responses with low IgE synthesis.

UI MeSH Term Description Entries
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000534 Alum Compounds Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds. Compounds, Alum
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine

Related Publications

Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
August 1981, The Journal of experimental medicine,
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
February 2004, International archives of allergy and immunology,
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
January 1974, European journal of immunology,
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
December 1983, Journal of immunology (Baltimore, Md. : 1950),
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
July 1978, Immunochemistry,
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
November 1978, Journal of immunology (Baltimore, Md. : 1950),
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
January 1984, Hybridoma,
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
July 2017, Journal of immunology (Baltimore, Md. : 1950),
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
April 1984, Molecular immunology,
Noriko Yanase, and Hiroko Toyota, and Kikumi Hata, and Seina Yagyu, and Takahiro Seki, and Mitsunori Harada, and Yasuki Kato, and Junichiro Mizuguchi
January 1982, Hybridoma,
Copied contents to your clipboard!